Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanobody-Based CD19/CD22 Tandem Dual CAR-T in R/R B-ALL
NCT06880913Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells, Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of nanobody-based CD19/CD22 tandem dual CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Peking University People's Hospital. Started Nov 2024; status: recruiting.
02
Drugs
nanobody-based CD19/CD22 tandem dual CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06880913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880913.